Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. - Wikidata - wikimedia - TriplyDB

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.

http://www.wikidata.org/entity/Q42562376

about

Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics Structural Insights into High Density Lipoprotein: Old Models and New Facts Niacin, an old drug with a new twist Regression of atherosclerosis: insights from animal and clinical studies New Era of Lipid-Lowering Drugs Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?Cholesterol, inflammation and innate immunity GPR109A and vascular inflammation The therapeutic role of niacin in dyslipidemia management Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice.Xanthohumol prevents atherosclerosis by reducing arterial cholesterol content via CETP and apolipoprotein E in CETP-transgenic mice.High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity.Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux.Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.Increased atherosclerosis in mice with vascular ATP-binding cassette transporter G1 deficiency--brief report.eNOS activation by HDL is impaired in genetic CETP deficiency.Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis.Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.Novel HDL-directed pharmacotherapeutic strategies.Atherosclerosis: current status of prevention and treatment.Using bioinformatics and systems genetics to dissect HDL-cholesterol genetics in an MRL/MpJ x SM/J intercross Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.Genetic variants in TLR2 and TLR4 are associated with markers of monocyte activation: the Atherosclerosis Risk in Communities MRI Study Targeting high density lipoproteins in the prevention of cardiovascular disease?Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties.Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study.In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption.Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

P2860

Q24634165-58A777FA-0B45-4B3E-9F06-A2D60698EAAD Q26765137-5BBEDE67-D94B-4409-880F-C195B6EAD975 Q26770434-41591659-B156-42DC-9C25-34D40B22D9E4 Q27002774-C5A6BDAE-265C-4345-BD40-FC73A3F02560 Q27028112-949C4E06-8C34-485B-897D-AE5840121C06 Q28072298-086DA1B1-CC72-4EDF-85B4-682DF564810A Q28080768-028582E1-4C79-492F-9506-917CD2DCC975 Q28086787-DB62C822-9DDF-43A5-9E27-3D3BFB3E0248 Q28086912-4B18B424-A6E3-4C97-8821-DCA971CFECD5 Q28287747-7D3BA2AD-8C6C-42A3-9B76-BA9B1CDAC1BF Q28304559-81A4278C-B781-47BD-B93F-37C8DDC73F5D Q29999973-0DB03CFE-BBE1-4598-B0F9-D6FAEEEA505C Q33972551-32E860E1-AF2D-4AA7-9CBE-DEA44CBC40DD Q34155049-74C1F939-4EB2-457D-80DF-7319ECF7C87B Q34181381-3D0FFF89-C7EE-4786-8575-1173FFFD898F Q34253290-35DCFA58-77E8-4D56-A395-BE6913AC31A5 Q34324735-97566083-CC27-4043-A98E-DDF51D662116 Q34482324-131A14CD-6552-4C2C-AB25-32CFF1BCD3A5 Q34493756-A8DCD59D-6FE6-454F-BC2F-7A7F98DEEA66 Q34797618-99C5EF9E-5E2F-42AD-88ED-95BDD270B5D7 Q34858025-7C1D02BB-19EC-41F6-96B5-A0610A510CDE Q35050020-6595FD00-722F-4C28-A0B2-C67DC4B5A229 Q35168995-63AC1E43-EDA5-4A9F-9095-D5C7A84DAE49 Q35380101-FE0930C8-E7F2-4263-83E2-A800B5EBE8D5 Q35615662-87038116-270E-4A82-898C-91E1251C8DF6 Q35747803-A36F57F6-BCE5-41A2-907B-DB878D21AD7B Q35860020-1FE6A7F2-DD14-4A3E-8C63-F2BCE97BCBB4 Q35902556-7C0E804B-8C40-461E-87BB-3D2E62A960A4 Q35958472-FBF2DC83-05F8-4D37-9E24-E25274F2E055 Q36141729-50284916-0B82-4849-8644-F4803521728C Q36158656-99DC4FAF-8EC2-4020-9B50-C41A86C3899D Q36453173-0ECC4514-C8EA-4266-8BAD-5FCD51B7D39C Q36496865-F86D20FD-2702-4C71-99EE-CB6F78C5B9EF Q36560360-1411789C-EC9A-45E7-AB9E-F90ABA17BBFA Q37013499-BBC18A97-9489-4676-9A20-51757CCF9895 Q37038670-2B345E3C-091F-4D67-9AEB-24D50A99A86A Q37162650-6073578E-BC8D-4768-AC5F-290A9D42128F Q37163072-FD300953-480F-4EB2-A6BD-9FBB1932397C Q37224981-F90C0D0C-EB00-4C27-9D41-3D736CD7323D Q37254899-A2EFA81A-DB3A-412E-BF5F-881ECD67A667

P2860

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.

http://www.wikidata.org/entity/Q42562376

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Cholesterol efflux potential a ...... nt with niacin or anacetrapib.

@en

Cholesterol efflux potential a ...... nt with niacin or anacetrapib.

@nl

type

label

Cholesterol efflux potential a ...... nt with niacin or anacetrapib.

@en

Cholesterol efflux potential a ...... nt with niacin or anacetrapib.

@nl

prefLabel

Cholesterol efflux potential a ...... nt with niacin or anacetrapib.

@en

Cholesterol efflux potential a ...... nt with niacin or anacetrapib.

@nl

P1433

Q42562376-DC57691B-932F-4E9A-AFA1-DBAE96CD8728

P1476

Q42562376-D8DDC09F-1642-47AD-ACA7-3DD29A91D5FF

P2093

Q42562376-3E397DAE-2E33-416D-813E-5E5D5836126A

Q42562376-47AC78E3-DCE8-443E-83DA-8F6A6C76026C

Q42562376-537762E8-9D51-4347-9135-53C5888A929C

Q42562376-8FBD2442-9906-44FE-8E00-20FC2E51C5EC

Q42562376-B1A77E75-33CA-4291-8F27-386D9B41F359

Q42562376-D2A85E91-3FDC-459F-8007-82BD7F604BEB

Q42562376-EF589B6D-9DE7-49A5-9584-93CA71CEE7AE

Q42562376-F5C878A5-C7D6-45AA-9DA0-0534DCA4ACC7

P2860

Q42562376-055F6A6D-20E5-4F84-AEFF-D9FA74361A77

Q42562376-06C15449-E900-485C-862B-9BDD46E80F8F

Q42562376-07809473-A9F7-4ED2-9565-584E9B78539D

Q42562376-0DD1B01F-0CE9-458D-9EAC-15C4057B9D83

Q42562376-10B6A61F-1FDD-4092-8728-15E59319C74E

Q42562376-1331041D-5879-4117-8474-0196091C5D0A

Q42562376-1A26B5F0-82AE-4DAE-8AE0-057E41121A69

Q42562376-1B3C8786-7B2C-42A8-B377-4623ED299F49

Q42562376-29476F0C-BF8C-4258-B5B9-411CF988B8EE

Q42562376-294E6E4D-2FAE-43D5-B9A0-1B8B6E9FAEB4

P304

Q42562376-234BC271-4CAA-433D-9BD7-E4D28D4502CE

P31

Q42562376-26B8CF98-0820-4DDE-912D-5876570994DE

P356

Q42562376-F38E2A42-3B2C-4BF0-9B32-1F422DB96283

P407

Q42562376-8DBB3113-6003-4E59-BE4B-79FC020B9C4E

P433

Q42562376-B574124C-A192-4658-9B5D-C3CE0242386B

P478

Q42562376-183D1AFA-9E93-41E4-98C6-BA7B2E62527F

P50

Q42562376-7A025B58-2C1C-4D68-BB25-3BFBAE3BC58F

P577

Q42562376-672F0193-4032-4EF1-8C42-0937B61130F9

P698

Q42562376-F3F5FF7F-846A-45D9-9B3F-453AC37B86B5

P921

Q42562376-AAE6FBBF-9B2F-436D-B814-A724B8D336CB

P932

Q42562376-42AEB0FF-2E38-4E5C-989F-5800100FFC76

P356

ATVBAHA.110.207142

P1433

Arteriosclerosis, Thrombosis, and Vascular Biology

P1476

Cholesterol efflux potential a ...... nt with niacin or anacetrapib.

@en

P2093

Alan R Tall

http://www.w3.org/2001/XMLSchema#string

Andrew K Taggart

http://www.w3.org/2001/XMLSchema#string

Brian Hubbard

http://www.w3.org/2001/XMLSchema#string

Carl P Sparrow

http://www.w3.org/2001/XMLSchema#string

Hongna Li

http://www.w3.org/2001/XMLSchema#string

Jelena Kling

http://www.w3.org/2001/XMLSchema#string

Tamara Pagler

http://www.w3.org/2001/XMLSchema#string

Tim Fisher

http://www.w3.org/2001/XMLSchema#string

P2860

Behavior of human apolipoprotein E in aqueous solutions and at interfaces

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

Effect of torcetrapib on the progression of coronary atherosclerosis

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

Effects of torcetrapib in patients at high risk for coronary events

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency.

The role of high-density lipoproteins in oxidation and inflammation.

P304

1430-1438

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/ATVBAHA.110.207142

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Laurent Yvan-Charvet

P577

2010-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20448206

http://www.w3.org/2001/XMLSchema#string

P921

P932

2917780

http://www.w3.org/2001/XMLSchema#string